Advertisement

Topics

Latest "Clinical Trial Protocol for Therapeutic MRI-guided High Intensity Focused Ultrasound Ablation of Uterine Fibroids in a 3T MRI Scanner" News Stories

05:06 EST 21st January 2019 | BioPortfolio

Here are the most relevant search results for "Clinical Trial Protocol for Therapeutic MRI-guided High Intensity Focused Ultrasound Ablation of Uterine Fibroids in a 3T MRI Scanner" found in our extensive news archives from over 250 global news sources.

More Information about Clinical Trial Protocol for Therapeutic MRI-guided High Intensity Focused Ultrasound Ablation of Uterine Fibroids in a 3T MRI Scanner on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Clinical Trial Protocol for Therapeutic MRI-guided High Intensity Focused Ultrasound Ablation of Uterine Fibroids in a 3T MRI Scanner for you to read. Along with our medical data and news we also list Clinical Trial Protocol for Therapeutic MRI-guided High Intensity Focused Ultrasound Ablation of Uterine Fibroids in a 3T MRI Scanner Clinical Trials, which are updated daily. BioPortfolio also has a large database of Clinical Trial Protocol for Therapeutic MRI-guided High Intensity Focused Ultrasound Ablation of Uterine Fibroids in a 3T MRI Scanner Companies for you to search.

Showing "Clinical Trial Protocol Therapeutic guided High Intensity Focused" News Articles 1–25 of 32,000+

Monday 21st January 2019

Horizon Discovery extends CRISPR Screening Service to primary human T cells

Extended screening service offers novel capabilities for immuno-oncology research in ex vivo T lymphocytes Service expansion parallels requirements of immunology-based research in drug discovery Cambridge, UK, 21 January, 2019: Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “the Company”), a global leader in gene editing and gene modulation technologies...


Microbiome analysis company Bio-Me inks biomarker deal with one of the top 10 consumer healthcare companies worldwide

Bio-Me AS using proprietary custom-made microbiome test to analyze samples from NTNU’s  HUNT BioBank 21 January 2019: Oslo, Norway Bio-Me, a pioneer in rapid gut microbiome analysis, has entered into an agreement with one of the top 10 consumer healthcare companies worldwide using Bio-Me’s Precision Microbiome Profiling (PMP) platform and the HUNT BioBank to identify gut micr...

Vertex Announces European Commission Approval for ORKAMBI® (lumacaftor/ivacaftor) for Treatment of Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease

Lumacaftor/ivacaftor is the first and only approved medicine in Europe to treat the underlying cause of cystic fibrosis for approximately 1,500 children aged 2 to 5 with two copies of the F508del mutation Vertex Pharmaceuticals (Europe) Limited today announced that the European Commission has granted approval of the label extension for ORKAMBI®...


US FDA issues guidance for clinical trial endpoints for approval of cancer drugs and biologics

The US FDA has issued the final guidance on clinical trial endpoints for the approval of cancer drugs and biologics. This according to the industry is a major benefit for the companies that export products to both the

Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology

Press Release 21 January 2019 Immunicum AB (publ) Announces Publication of Phase  I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology Immunicum AB (publ; IMMU.ST) announced today that the final data analysis from the exploratory clinical study of ilixadencel in patients with advanced hepatocellular carcinoma (HCC) has been pub...

Gore Introduces GORE® TAG® Conformable Thoracic Stent Graft with Reduced Profiles in Europe

Reduced profiles on most commonly used sizes allow the device to be introduced through a smaller sheath while maintaining the state-of-the-art conformable design W. L. Gore & Associates, Inc. (Gore) today introduced reduced profiles for the most commonly used diameters of the GORE® TAG® Conformable Thoracic Stent

Alnylam Pharmaceuticals and Medison Pharma Partner to Commercialize RNAi Therapeutics in Israel

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Medison Pharma, Israel’s leading commercial partner for innovative pharmaceuticals, announced today an exclusive agreement to commercialize ONPATTR

Microbial Discovery Group Kicks Off 2019 with a New Product Line for the Industrial and Institutional Cleaning Market

Backed by sound science and research with two-day shipping and packaging capabilities, Microbial Discovery Group helps industrial and institutional suppliers stand out with trusted microbial products. FRANKLIN, Wis. (PRWEB) January 21, 2019 Microbial Discovery Group (MDG), a leading Bacillus fermentation company, announced their newest product line, SporActiv™, for the industrial and institutio...

BookDoc partners Special Olympics Asia Pacific to encourage active lifestyles among people with intellectual disabilities

SINGAPORE, Jan. 21, 2019 /PRNewswire/ -- BookDoc today signed a memorandum of understanding with Special Olympics Asia Pacific. The partnership aims to improve the health and fitness of people with intellectual disabilities across the Asia Pacific region by allowing them to keep track of their daily activity through BookDoc's wellness reward application, BookDoc Activ.

Kyn Therapeutics, Celgene partner on immuno-oncology therapies development

The collaboration will combine the immuno-oncology expertise and pipeline of Kyn Therapeutics with the capabilities of Celgene in development and commercialization of drugs in areas of high unmet The post Kyn Therapeutics, Celgene partner on immuno-oncology therapies development appeared first on Pharmaceutical Business review.

Neuroimmunology Drug Development [Report Updated: 17122018] Prices from USD $7995

Neuroimmunology Drug DevelopmentSummaryNeuroimmunology is expected to be an area that will witness strong growth in the future due to factors such as deeper understanding of the underlying disease pathology, advancements in neurogenetics, and potential of these drugs that can contribute to targeted therapy. Pipeline drugs targeting a number of neurology indications are being developed; however, th...

Biomarkers and Companion Diagnostics in Oncology [Report Updated: 17122018] Prices from USD $7995

Biomarkers and Companion Diagnostics in OncologySummaryA biomarker is a defined molecular characteristic, for example a genetic mutation, that can tell a physician more about a patient's disease state, or how they might respond to treatment. Predictive biomarkers indicate how likely a patient is to respond to a treatment, and are used in clinical decision making. In some cases, a patient must poss...

Global Rheumatic Disorders Drugs Market to 2024 Increased Uptake of IL Inhibitors and JAK Inhibitors to Drive Growth as TNF Inhibitors Face Patent Expiry [Report Updated: 01012019] Prices from USD $4995

Global Rheumatic Disorders Drugs Market to 2024 Increased Uptake of IL Inhibitors and JAK Inhibitors to Drive Growth as TNF Inhibitors Face Patent ExpirySummaryThe rheumatic disorder therapy area is multidisciplinary in nature and encompasses conditions that affect joints, connective tissue, ligaments, tendons, cartilage, bone and muscle and which are characterized by chronic pain and a consequen...

Global Women's Health Drugs Market to 2024 Influx of New Products Including Orilissa, Relugolix and Bremelanotide to Diversify Landscape and Drive Growth [Report Updated: 01012019] Prices from USD $4995

Global Women's Health Drugs Market to 2024 Influx of New Products Including Orilissa, Relugolix and Bremelanotide to Diversify Landscape and Drive GrowthSummaryThe women's health therapy area covers medical disorders that affect females only, primarily disorders of the female reproductive system, including those associated with menstruation, conception, pregnancy, childbirth and menopause. Many o...

Global Clinical Trials Current Trends and Recent Advancement [Report Updated: 01012019] Prices from USD $2995

Global Clinical Trials Current Trends and Recent AdvancementSummaryGBI Research's latest report, Global Clinical Trials Current Trends and Recent Advancement, provides an indepth assessment of the current trends in the number of clinical trials globally, Top 10 therapy area, geography wise clinical trials, YOY clinical trials in top 10 therapy area.Major sponsor are focusing on oncology as Cance...

Emerging Gene Therapies Trends within the Technological, Clinical, Regulatory and Competitive Landscape [Report Updated: 03012019] Prices from USD $2995

Emerging Gene Therapies Trends within the Technological, Clinical, Regulatory and Competitive LandscapeSummaryGBI Research's latest report Emerging Gene Therapies Trends within the Technological, Clinical, Regulatory and Competitive Landscape provides a comprehensive overview of the emerging gene therapy market. The report discusses gene therapy and the technology behind gene editing, outlining ...

Innovation Tracking Factbook 2018: An Assessment of the Pharmaceutical Pipeline [Report Updated: 14122018] Prices from USD $2995

Innovation Tracking Factbook 2018: An Assessment of the Pharmaceutical PipelineSummaryGBI Research's latest report Innovation Tracking Factbook 2018: An Assessment of the Pharmaceutical Pipeline is a comprehensive, granular analysis of the 25,284 products currently in the pharmaceutical industry pipeline, from the Discovery stage through to Preregistration and split into key therapy areas and indi...

PI3K Signaling Pathway Analysis: A Shifting Marketed and Pipeline Product Landscape, as Blockbusters Expire and Development Moves Towards Downstream Targets [Report Updated: 01072018] Prices from USD $2995

PI3K Signaling Pathway Analysis: A Shifting Marketed and Pipeline Product Landscape, as Blockbusters Expire and Development Moves Towards Downstream TargetsSummaryGBI Research's latest report, PI3K Signaling Pathway Analysis: A Shifting Marketed and Pipeline Product Landscape, as Blockbusters Expire and Development Moves Towards Downstream Targets, provides a comprehensive assessment of the market...

Allergic Asthma Global Clinical Trials Review, H2, 2018 [Report Updated: 25102018] Prices from USD $2500

Allergic Asthma Global Clinical Trials Review, H2, 2018SummaryGlobalData's clinical trial report, Allergic Asthma Global Clinical Trials Review, H2, 2018" provides an overview of Allergic Asthma clinical trials scenario. This report provides top line data relating to the clinical trials on Allergic Asthma. Report includes an overview of trial numbers and their average enrollment in top countries c...

Sunday 20th January 2019

Quotation of the Day

The first Quality of an Historian is to be true & impartial; the next to be interesting. David Hume The same could be said of any researcher or even blogger (at least those bloggers like myself focused on advancing knowledge). I found this quotation in the very interesting book The Infidel and the Professor: David Hume, Adam Smith and the Frien...

Study highlights need for reliable therapeutic targets for prevention, treatment of cardiovascular diseases

CVD (cardiovascular diseases) are proven to be the leading cause of deaths throughout the world. If statistics are reviewed, almost four out of five deaths are due to myocardial infarction or stroke.

Early studies and recent clinical trials on nerve growth factor

Nerve growth factor has been playing an important role in development of adult neurobiology. This is because of the regulatory functions that it possesses on survival, growth and differentiation of nerve cells in both of the central and peripheral nervous systems.

Fiderstat could be used as chemopreventative drug for intestinal cancers caused by APC gene mutations

Colorectal Cancer has now become one of the leading causes of death. Studies indicate that smoking, low physical activities and high-fat diet are a major risk factor for colorectal cancer.

SanBio: Addition of a Cerebral Hemorrhage Program for SB623 Regenerative Cell Medicine

At a meeting held today, the Board of Directors of SanBio Co., Ltd. (hereinafter, the “Company”) resolved to add a program for treatment of chronic motor deficit from cerebral hemorrhage as a new indication for SB623, a regenerative cell medicine developed by the Group. (Hereinafter, the “Group” refers to two companies, SanBio Co., Ltd., and SanBio...

China’s clinical trial shake-up

As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks